GP681

DRUG2 trials

Sponsors

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Conditions

Healthy VolunteersHepatic Impairment

Phase 1

A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers

CompletedNCT05789342

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Healthy Volunteers

Start: 2023-02-15End: 2023-10-31Updated: 2023-11-14

GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

CompletedNCT05814926

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Healthy Volunteers, Hepatic Impairment

Start: 2023-04-26End: 2023-10-20Updated: 2023-11-15

Related Papers

A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza.

2026-03-23

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism

Frontiers in Pharmacology2025-04-113 citations